| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addressing challenges in low-income and middle-income countries through novel radiotherapy research opportunities
|
Abdel-Wahab, May
|
|
|
25 |
6 |
p. e270-e280
|
artikel
|
| 2 |
Addressing oncology's contribution to climate change
|
Berg, Christine D
|
|
|
25 |
6 |
p. 690-691
|
artikel
|
| 3 |
Biden administration delays long-awaited ban on menthol cigarettes
|
Furlow, Bryant
|
|
|
25 |
6 |
p. 698-699
|
artikel
|
| 4 |
Cancer on the agenda during IAEA Director General's visit to Chile
|
Das, Manjulika
|
|
|
25 |
6 |
p. 701-702
|
artikel
|
| 5 |
Combining the prognostic role of age with molecular advances in the understanding of endometrial cancer
|
Senguttuvan, Rosemary N
|
|
|
25 |
6 |
p. 688-690
|
artikel
|
| 6 |
Correction to Lancet Oncol 2023; 24: 1002–17
|
|
|
|
25 |
6 |
p. e234
|
artikel
|
| 7 |
Correction to Lancet Oncol 2024; 25: e139–51
|
|
|
|
25 |
6 |
p. e234
|
artikel
|
| 8 |
Correction to Lancet Oncol 2024; 25: e126–35
|
|
|
|
25 |
6 |
p. e234
|
artikel
|
| 9 |
Cryptic metastatic calcification after radical nephrectomy in a patient with renal cell carcinoma
|
Huang, Shan
|
|
|
25 |
6 |
p. e281
|
artikel
|
| 10 |
Current regulatory status in China of drugs withdrawn from the US FDA accelerated pathway: implications for regulation globally
|
Luo, Xingxian
|
|
|
25 |
6 |
p. 703-706
|
artikel
|
| 11 |
Directed acyclic graphs to foster transparency and scientific dialogue
|
Rueegg, Corina S
|
|
|
25 |
6 |
p. 693-694
|
artikel
|
| 12 |
Effect of multitarget faecal immunochemical testing on colorectal cancer screening strategies
|
Lu, Zhenhua
|
|
|
25 |
6 |
p. e226
|
artikel
|
| 13 |
Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis
|
Zosso-Pavic, Matea
|
|
|
25 |
6 |
p. 770-778
|
artikel
|
| 14 |
ESTRO 2024
|
Collingridge, David
|
|
|
25 |
6 |
p. 699-700
|
artikel
|
| 15 |
Finding the health-care expenditure that drives variation in cancer survival
|
Rutherford, Mark J
|
|
|
25 |
6 |
p. 684-685
|
artikel
|
| 16 |
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
|
Fürstenau, Moritz
|
|
|
25 |
6 |
p. 744-759
|
artikel
|
| 17 |
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia
|
Rogers, Kerry A
|
|
|
25 |
6 |
p. 685-687
|
artikel
|
| 18 |
GDPR and data sharing: the Pediatric Cancer Data Commons experience
|
Wyatt, Kirk D
|
|
|
25 |
6 |
p. e227
|
artikel
|
| 19 |
Global cooperation and early access—clinical outcomes matter
|
Tibau, Ariadna
|
|
|
25 |
6 |
p. 687-688
|
artikel
|
| 20 |
IAEA facilitates sharing oncology expertise in Asia–Pacific region
|
Gourd, Elizabeth
|
|
|
25 |
6 |
p. 695
|
artikel
|
| 21 |
Inadequate government funding for UK hospices affects palliative care
|
Gourd, Elizabeth
|
|
|
25 |
6 |
p. 697-698
|
artikel
|
| 22 |
Initiatives to target cancer care and research in Africa
|
Adepoju, Paul
|
|
|
25 |
6 |
p. 696-697
|
artikel
|
| 23 |
International variation in chemotherapy use in cancer – Authors' reply
|
Barclay, Matthew E
|
|
|
25 |
6 |
p. e232
|
artikel
|
| 24 |
International variation in chemotherapy use in cancers
|
Han, Wei
|
|
|
25 |
6 |
p. e231
|
artikel
|
| 25 |
Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study
|
Sant, Milena
|
|
|
25 |
6 |
p. 731-743
|
artikel
|
| 26 |
Medical debt of people with cancer in the USA
|
Burki, Talha
|
|
|
25 |
6 |
p. e235
|
artikel
|
| 27 |
Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis
|
Naci, Huseyin
|
|
|
25 |
6 |
p. 760-769
|
artikel
|
| 28 |
PD-L1 as a predictive factor for non-small-cell lung cancer prognosis
|
Chen, Long
|
|
|
25 |
6 |
p. e233
|
artikel
|
| 29 |
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial
|
Necchi, Andrea
|
|
|
25 |
6 |
p. 720-730
|
artikel
|
| 30 |
Production and regulatory issues for theranostics
|
Giammarile, Francesco
|
|
|
25 |
6 |
p. e260-e269
|
artikel
|
| 31 |
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials
|
Wakkerman, Famke C
|
|
|
25 |
6 |
p. 779-789
|
artikel
|
| 32 |
Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system
|
Bryant, Alex K
|
|
|
25 |
6 |
p. 802-810
|
artikel
|
| 33 |
Protests in South Africa over unused cancer-treatment fund
|
Adepoju, Paul
|
|
|
25 |
6 |
p. 700-701
|
artikel
|
| 34 |
Putting patient safety first: a global imperative
|
The Lancet Oncology,
|
|
|
25 |
6 |
p. 683
|
artikel
|
| 35 |
Quantification of the environmental impact of radiotherapy and associated secondary human health effects: a multi-institutional retrospective analysis and simulation
|
Lichter, Katie E
|
|
|
25 |
6 |
p. 790-801
|
artikel
|
| 36 |
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology
|
Lapi, Suzanne E
|
|
|
25 |
6 |
p. e236-e249
|
artikel
|
| 37 |
Reducing the environmental impact of immunotherapy treatment
|
Briggs, Sarah E W
|
|
|
25 |
6 |
p. 691-693
|
artikel
|
| 38 |
Stereotactic ablative radiotherapy for primary kidney cancer
|
Bhargava, Priyank
|
|
|
25 |
6 |
p. e228
|
artikel
|
| 39 |
Stereotactic ablative radiotherapy for primary kidney cancer
|
Brown, Nicholas
|
|
|
25 |
6 |
p. e229
|
artikel
|
| 40 |
Stereotactic ablative radiotherapy for primary kidney cancer – Authors' reply
|
Siva, Shankar
|
|
|
25 |
6 |
p. e230
|
artikel
|
| 41 |
The burden of cardiovascular disease and risk for subsequent major adverse cardiovascular events in survivors of childhood cancer: a prospective, longitudinal analysis from the St Jude Lifetime Cohort Study
|
Hammoud, Rawan A
|
|
|
25 |
6 |
p. 811-822
|
artikel
|
| 42 |
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
|
Li, Bob T
|
|
|
25 |
6 |
p. 707-719
|
artikel
|
| 43 |
Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics
|
Scott, Andrew M
|
|
|
25 |
6 |
p. e250-e259
|
artikel
|
Tijdschrift beschrijving